Advantages of therapy with risperidone long-acting injectable antipsychotic in first-episode schizophrenic patients (CROSBI ID 598477)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Petrić, Daniela ; Vučić Peitl, Marija ; Graovac, Mirjana ; Kastelan, Ana ; Frančišković, Tanja ; Racki, Valentino
engleski
Advantages of therapy with risperidone long-acting injectable antipsychotic in first-episode schizophrenic patients
Objective Aim of the paper is to assess the therapeutic effieciency of risperidone long-acting injectable antipsychotic in first-episode schizophrenia compared to those with two, three or more episodes. Previous research shows that 50% of first-episode schizophrenia patients relapse within a year as a result of non-compliance or partial compliance in taking the antipsychotic medication (Emsley et al.2008 ; McEvoy et al.2007 ; Gitilin et al.2001 ; Chen et al. 2010, Lauriello et al.2012, Detke et al. 2012). Treating patients with risperidone long-acting injectable antipsychotic avoids the issue of non-compliance which leads to lower relapse rates, better remission and recovery (Emlsley et al.2012 ; Lambert et al.2011 ; Peuskens et al.2011). Method The research included 35 patients aged 14 to 30 years who were diagnosed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnostic criteria. They were divided into three groups according to the number of psychotic episodes: 1. First psychotic episode, 2. Second psychotic episode, 3. Three or more psychotic episodes. All patients were assessed four times over one year from the start of their respective treatment (start of treatment, 3rd, 6th and 12th month) using the following clinical scales: Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression – Severity of Illness Scale (CGI-S), Clinical Global Impression – Improvement Scale (CGI-I), Personal and Social Performance Scale (PSP). Results First-episode patients had a better response to treatment with long-acting risperidone antipsychotic when compared to second episode patients and much better compared to the patients with three or more episodes. Conclusion Earlier application of risperidone long-acting injectable antipsychotic can lead to better responses to therapy, lower relapse rates, achieving remission and full recovery, especially in first-episode patients.
schizophrenia; long acting drug; risperidone; first episode
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
n.a.-n.a..
2013.
objavljeno
Podaci o matičnoj publikaciji
Abstract CD-ROM
WFSBP
Kyoto: World Federation of Societies of Biological Psychiatry
Podaci o skupu
11th World Congress of Biological psychiatry
poster
23.06.2013-27.06.2013
Kyoto, Japan